Last Updated: November 16, 2026

JESDUVROQ Drug Patent Profile

« Back to Dashboard


Which patents cover Jesduvroq, and when can generic versions of Jesduvroq launch?

Jesduvroq is a drug marketed by Glaxosmithkline and is included in one NDA. There are six patents protecting this drug.

The generic ingredient in JESDUVROQ is daprodustat. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the daprodustat profile page.

DrugPatentWatch® Generic Entry Outlook for Jesduvroq

Jesduvroq will be eligible for patent challenges on February 1, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 11, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for JESDUVROQ?
  • What are the global sales for JESDUVROQ?
  • What is Average Wholesale Price for JESDUVROQ?
Summary for JESDUVROQ
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for JESDUVROQ
Generic Entry Date for JESDUVROQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JESDUVROQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GlaxoSmithKlinePhase 4
USRC Kidney ResearchPhase 4

See all JESDUVROQ clinical trials

US Patents and Regulatory Information for JESDUVROQ

JESDUVROQ is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of JESDUVROQ is ⤷  Start Trial.

This potential generic entry date is based on patent 8,324,208.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-005 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-004 Feb 1, 2023 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-005 Feb 1, 2023 DISCN Yes No 11,643,397 ⤷  Start Trial Y ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-005 Feb 1, 2023 DISCN Yes No 11,117,871 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for JESDUVROQ

When does loss-of-exclusivity occur for JESDUVROQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 07260837
Patent: Prolyl hydroxylase inhibitors
Estimated Expiration: ⤷  Start Trial

Jordan

Patent: 34
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 526
Patent: INHIBITEURS DE PROLYLE HYDROXYLASE
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 37922
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 0810602
Patent: Prolyl hydroxylase inhibitors
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JESDUVROQ around the world.

Country Patent Number Title Estimated Expiration
Australia 2018330994 Crystal form of GSK1278863 and preparation method and pharmaceutical use thereof ⤷  Start Trial
Canada 3112277 FORME CRISTALLINE DE GSK1278863 ET SON PROCEDE DE PREPARATION ET SON UTILISATION PHARMACEUTIQUE (CRYSTAL FORM OF GSK1278863 AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF) ⤷  Start Trial
China 111093668 GSK1278863 的晶型及其制备方法和制药用途 (CRYSTAL FORM OF GSK1278863 AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF) ⤷  Start Trial
European Patent Office 3682884 FORME CRISTALLINE DE GSK1278863 ET SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE (CRYSTAL FORM OF GSK1278863 AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Jesduvroq Market Dynamics and Financial Trajectory: Daprodustat Sales, Competition, Patents, and Commercial Outlook

Last updated: October 5, 2026

Jesduvroq, GSK’s daprodustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in the United States for anemia caused by chronic kidney disease in adults who have been receiving dialysis for at least four months. Its commercial opportunity is concentrated in the U.S. dialysis market, where it competes with injectable erythropoiesis-stimulating agents, iron therapy, and newer oral HIF-PH inhibitors. The product has strategic differentiation through oral administration, but its label is narrower than initially expected and its financial contribution remains immaterial relative to GSK’s major respiratory, HIV, oncology, and vaccine franchises.

Public disclosures through 2024 do not provide a separate Jesduvroq revenue line. GSK reports the product within broader commercial categories, preventing a reliable standalone sales trajectory. The principal investment question is whether daprodustat can convert a convenience advantage into meaningful dialysis-center adoption before Vafseo and established injectable therapies limit market share.

What is Jesduvroq and what is its FDA-approved use?

Jesduvroq is the U.S. brand name for daprodustat, an oral HIF-PH inhibitor developed by GlaxoSmithKline. The FDA approved it on February 1, 2023, for anemia caused by chronic kidney disease in adults who have been receiving dialysis for at least four months.[1]

Attribute Jesduvroq
Active ingredient Daprodustat
Drug class HIF prolyl hydroxylase inhibitor
U.S. sponsor GlaxoSmithKline
U.S. approval date February 1, 2023
Approved population Adults with CKD-related anemia receiving dialysis for at least four months
Dosage form Oral tablets
Dosing Once daily, with dose adjusted according to hemoglobin response
FDA pathway New drug application
Initial U.S. launch 2023
Main therapeutic alternatives Epoetin alfa, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, iron therapy, Vafseo

Daprodustat activates the HIF pathway by inhibiting prolyl hydroxylase enzymes. The mechanism increases endogenous erythropoietin production and changes iron-handling biology. This differs from conventional ESAs, which directly provide recombinant erythropoietin through injection.

The FDA label contains a boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access. The drug is not indicated as a substitute for red-blood-cell transfusion when immediate correction of anemia is required.[1]

How large is the Jesduvroq addressable market?

The U.S. opportunity is substantial in patient count but constrained by the product label and procurement structure. The U.S. dialysis population is approximately 550,000 to 600,000 patients, with anemia treatment largely managed through dialysis providers and nephrologists.[2]

Jesduvroq does not address the entire CKD anemia market. Its approved population excludes adults with CKD who are not receiving dialysis. That restriction materially reduces the addressable population compared with the broader pre-approval development strategy for daprodustat.

Market segmentation

Segment Jesduvroq relevance
Hemodialysis patients Core approved market
Peritoneal dialysis patients Included if receiving dialysis for at least four months
Nondialysis CKD Not approved in the U.S.
Hospitalized patients needing immediate correction Not an appropriate replacement for transfusion
Patients with uncontrolled hypertension or high thrombotic risk Significant prescribing constraint
Dialysis-center formularies Critical commercial gatekeeper

The market is concentrated. Large dialysis organizations, including Fresenius Medical Care and DaVita, influence treatment protocols, formulary decisions, purchasing terms, and conversion rates from injectable ESAs. That structure can reduce the value of a prescription-level convenience advantage because treatment decisions are often made at the provider or center level.

How does Jesduvroq compare with Vafseo and injectable ESAs?

Jesduvroq competes on oral administration, while injectable ESAs benefit from established clinical pathways, extensive utilization data, and entrenched dialysis-center infrastructure.

Product Ingredient Administration U.S. status through 2024 Competitive position
Jesduvroq Daprodustat Oral Approved in 2023 for dialysis patients First U.S. oral HIF-PH inhibitor, but narrow label
Vafseo Vadadustat Oral Approved in March 2024 for dialysis patients Direct oral competitor with later entry
Epogen/Procrit Epoetin alfa Injection Long-established Low-cost, widely used ESA
Aranesp Darbepoetin alfa Injection Long-established Longer-acting ESA
Mircera Methoxy polyethylene glycol-epoetin beta Injection Approved Long-acting ESA option
Roxadustat Roxadustat Oral Not approved in the U.S. through mid-2024 International HIF-PH competitor

Vafseo is the most direct U.S. competitor. Akebia Therapeutics received FDA approval for vadadustat on March 27, 2024, for anemia due to CKD in adults on dialysis.[3] Vafseo’s entry limits the period during which Jesduvroq could establish itself as the only oral HIF-PH option in the United States.

The established ESA market retains important advantages:

  • Generic epoetin products are widely available.
  • Dialysis providers have protocols for ESA dose adjustment.
  • Reimbursement and supply chains are established.
  • Long-term safety and utilization experience is extensive.
  • Switching patients may create monitoring and operational costs.

The HIF-PH class has a potential clinical advantage in reducing injection burden. Its commercial disadvantage is the need to establish comparative value against inexpensive and familiar therapies.

What clinical evidence supports Jesduvroq adoption?

The FDA approval was based principally on phase 3 ASCEND studies evaluating daprodustat in dialysis and nondialysis CKD populations. In dialysis patients, daprodustat demonstrated hemoglobin efficacy comparable to conventional ESAs within the clinical trial framework.[4]

The commercial relevance of the evidence is mixed. The dialysis results support use as an oral anemia treatment, but the nondialysis results did not produce a U.S. indication. That outcome removed a major part of the original market thesis.

The FDA’s safety review also limits aggressive positioning. HIF-PH inhibitors carry class-related cardiovascular concerns, and daprodustat’s label requires careful hemoglobin management and warnings around thrombotic and cardiovascular events.[1] The treatment is therefore more likely to be used selectively in patients for whom oral administration, injection avoidance, or ESA management is commercially valuable.

What is the financial trajectory of Jesduvroq?

GSK has not reported standalone Jesduvroq revenue in its public annual reporting through 2023 or the first half of 2024. The product is not comparable in financial scale to GSK’s principal growth products, such as Trelegy, Shingrix, Arexvy, Nucala, and the company’s HIV portfolio.[5]

Financial trajectory

Period Commercial status Financial interpretation
2023 U.S. launch year Initial formulary access, limited historical sales base
2024 First full commercial year; Vafseo entered market Share-building challenged by direct oral competition
2025 onward Mature dialysis-market competition Growth depends on center adoption, pricing, and conversion from ESAs

Jesduvroq’s likely financial profile is a modest specialty-pharmaceutical contribution rather than a major GSK growth driver. The U.S. label caps the addressable market, and the product lacks the international scale of GSK’s largest brands. GSK’s decision to discontinue daprodustat development in certain non-U.S. settings after regulatory setbacks also reduced the probability of a broad global commercial platform.[5]

Revenue upside depends on four variables:

  1. The percentage of dialysis centers that place Jesduvroq on formulary.
  2. The percentage of eligible patients converted from injectable ESAs.
  3. Net price after discounts and dialysis-provider contracting.
  4. Persistence of treatment and refill adherence.

The product could generate durable specialty revenue if GSK secures center-level contracts and establishes oral HIF-PH therapy as a standard alternative. It is less likely to become a blockbuster because the approved population is narrow, the competitive field is expanding, and injectable ESAs remain entrenched.

What patents protect Jesduvroq and when does it lose exclusivity?

Jesduvroq’s U.S. exclusivity rests on regulatory exclusivity and patents covering daprodustat, pharmaceutical compositions, and therapeutic use. The FDA approved the drug under a new drug application, creating five years of new chemical entity exclusivity from the approval date, subject to applicable Paragraph IV timing rules.[6]

The five-year NCE period is expected to run until February 1, 2028, unless a patent challenge or other statutory event affects the timing of generic approval. The practical generic-entry date may occur later if listed patents remain enforceable or if a generic applicant does not successfully challenge them.

Exclusivity category Expected timing
FDA approval February 1, 2023
Five-year NCE exclusivity Approximately through February 1, 2028
Patent protection Potentially beyond statutory NCE exclusivity, depending on listed patent terms
Pediatric exclusivity No separate six-month award identified in the cited public materials
Generic entry Dependent on ANDA filing, Paragraph IV litigation, patent outcomes, and court-imposed stays

A precise patent-expiration analysis requires the current Orange Book patent listing and individual patent-term calculations. The commercial risk is not limited to composition-of-matter protection. Formulation, dosing, and method-of-use patents may delay or narrow generic entry even after NCE exclusivity ends.

What is the Orange Book and Paragraph IV status of Jesduvroq?

Jesduvroq is an FDA-approved small-molecule drug and is eligible for Orange Book patent listing. Generic competition would normally proceed through an abbreviated new drug application. A Paragraph IV certification could allege that a listed patent is invalid, unenforceable, or not infringed.

Through mid-2024, no high-profile public Paragraph IV litigation had materially altered the Jesduvroq commercial outlook. The more immediate competitive threat came from Vafseo, which is not a generic version of daprodustat and does not require a patent challenge against Jesduvroq to enter the market.

A generic daprodustat applicant would face several commercial barriers:

  • Limited market size relative to development and litigation costs.
  • Potential patent layering across composition, formulation, and use claims.
  • Dialysis-center contracting requirements.
  • Clinical switching and safety-monitoring considerations.
  • Competition from other oral HIF-PH inhibitors.

What formulation and method-of-use protections matter?

The principal technical value of Jesduvroq is its oral systemic delivery. Relevant patent categories may include:

  • Daprodustat composition-of-matter claims.
  • Solid oral dosage forms.
  • Tablet formulations and manufacturing processes.
  • Dosing regimens for dialysis patients.
  • Hemoglobin-management methods.
  • Use in patients transitioning from injectable ESAs.
  • Combination use with iron therapy.

Method-of-use patents are commercially relevant because the U.S. approval is limited to dialysis patients. Claims directed to dialysis-specific dosing or hemoglobin targets could remain important even if broad composition protection is challenged.

Manufacturing barriers are less severe than for biologics. Daprodustat is a synthetic small molecule, so a generic manufacturer does not need to reproduce a biologic cell line or complex protein process. The main barriers are patent clearance, bioequivalence, regulatory approval, and access to dialysis-provider purchasing channels.

What licensing deals and corporate transactions affect Jesduvroq?

GSK is the principal commercial sponsor of daprodustat. The product originated in GSK’s internal pharmaceutical research and was developed through GSK’s ASCEND clinical program. No major third-party licensing transaction has been central to the U.S. Jesduvroq commercial story through mid-2024.

The absence of a major licensing deal limits external validation of the asset’s commercial value. It also means that GSK retains direct control over pricing, market access, manufacturing strategy, and lifecycle management.

What litigation and settlement agreements affect Jesduvroq?

No major U.S. patent litigation settlement involving a generic daprodustat applicant had become a central public market event through mid-2024. The relevant legal risk remains prospective rather than litigation-driven.

The largest near-term competitive event is regulatory competition from Vafseo, not an ANDA challenge. If Paragraph IV litigation emerges later, its business impact will depend on whether the challenger targets composition patents or only later-expiring formulation and method-of-use claims.

How strong is the Jesduvroq patent estate?

The patent estate is strategically useful but commercially exposed to the limits of the approved market. A strong composition patent could support protection beyond the five-year NCE period. However, the product’s value is constrained by:

  • A dialysis-only U.S. indication.
  • Direct oral competition from vadadustat.
  • Generic ESA pricing pressure.
  • Cardiovascular safety warnings.
  • Limited nondialysis opportunity.
  • Concentrated buyer power among dialysis providers.

Patent strength is therefore only one component of commercial durability. Even a legally strong estate may support moderate rather than high revenue if the product cannot achieve broad formulary adoption.

What generic launch scenarios exist for Jesduvroq?

Scenario 1: Delayed generic entry

GSK maintains enforceable composition or key use patents beyond the NCE period. Generic entry is deferred, allowing Jesduvroq to compete primarily with Vafseo and ESAs.

Scenario 2: Early Paragraph IV challenge

A generic applicant challenges listed patents near the end of the NCE period. Litigation produces a 30-month stay or settlement, delaying launch while preserving some branded market share.

Scenario 3: Authorized generic or rapid generic erosion

A successful patent challenge or weak patent position permits entry soon after NCE expiry. Net price and volume decline rapidly, particularly if multiple manufacturers enter simultaneously.

The most probable commercial erosion pattern for a small dialysis product is gradual formulary substitution rather than a large retail-prescription shock. Dialysis-center contracts and clinical protocols can slow initial switching, but price competition can accelerate once a generic has achieved operational acceptance.

What is the competitive outlook for Jesduvroq?

Jesduvroq has a defensible but limited position. Its main advantages are first-mover status in the U.S. oral HIF-PH category and the convenience of oral treatment. Its main disadvantages are the narrow label, strong ESA incumbency, cardiovascular warnings, and Vafseo’s approval in 2024.

The product’s financial trajectory is best characterized as a niche growth opportunity within GSK’s portfolio. It is unlikely to materially change consolidated GSK revenue unless oral HIF-PH adoption becomes widespread across dialysis networks or the company obtains meaningful label expansion. The nondialysis indication, which could have materially increased market size, was not secured in the United States.

Key Takeaways

  • Jesduvroq is daprodustat, an oral HIF-PH inhibitor marketed by GSK.
  • The FDA approved it on February 1, 2023, only for adults with CKD anemia receiving dialysis for at least four months.
  • The U.S. label excludes the broader nondialysis CKD market.
  • GSK has not publicly reported standalone Jesduvroq revenue through mid-2024.
  • Vafseo, approved in March 2024, is the principal direct U.S. oral competitor.
  • Injectable ESAs remain strong competitors because of low cost, established protocols, and dialysis-center infrastructure.
  • NCE exclusivity is expected to extend approximately through February 1, 2028.
  • Generic-entry timing depends on Orange Book listings, Paragraph IV activity, patent litigation, and settlement terms.
  • Jesduvroq is more likely to become a durable specialty product than a major GSK revenue driver.
  • The principal commercial risk is limited market penetration, not immediate generic erosion.

FAQs

Is Jesduvroq approved for nondialysis chronic kidney disease?

No. The U.S. approval is limited to adults with CKD-related anemia who have been receiving dialysis for at least four months.[1]

Is Jesduvroq a biologic drug?

No. Daprodustat is a synthetic small-molecule oral drug. It is not a biologic and does not face the biosimilar pathway used for monoclonal antibodies and other biologics.

Is Vafseo a generic version of Jesduvroq?

No. Vafseo contains vadadustat, a different HIF-PH inhibitor developed by Akebia Therapeutics. It competes directly with Jesduvroq but does not copy daprodustat.

What is the main reimbursement risk for Jesduvroq?

The main risk is dialysis-provider control over anemia-treatment protocols and purchasing. A treatment with a higher net cost than injectable ESAs may require evidence of operational or clinical value to secure broad formulary adoption.

Can Jesduvroq become a blockbuster drug?

That outcome is unlikely under the current U.S. label. The dialysis-only indication, direct oral competition, established ESAs, cardiovascular warnings, and absence of a separately disclosed high-growth revenue trajectory limit blockbuster potential.

References

  1. U.S. Food and Drug Administration. (2023). Jesduvroq (daprodustat) prescribing information. FDA.

  2. United States Renal Data System. (2023). 2023 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases.

  3. U.S. Food and Drug Administration. (2024). Vafseo (vadadustat) approval announcement and prescribing information. FDA.

  4. GlaxoSmithKline. (2023). Daprodustat clinical development program and ASCEND study results. GSK.

  5. GSK plc. (2024). Annual report 2023. GSK.

  6. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.